Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Abdel Rahman, Omar M ^a   Elsayed, Zeinab ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; PLACEBO; YTTRIUM 90; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SORAFENIB; YTTRIUM;

ADVERSE OUTCOME; ARTIFICIAL EMBOLISM; CANCER MORTALITY; CANCER THERAPY; COCHRANE LIBRARY; EMBASE; HUMAN; INFORMATION RETRIEVAL; INOPERABLE CANCER; LIVER CELL CARCINOMA; MEDLINE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RADIOEMBOLIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCISEARCH; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ARTIFICIAL EMBOLIZATION; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; LIVER NEOPLASMS; META ANALYSIS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; MICROSPHERES; NIACINAMIDE; PHENYLUREA COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YTTRIUM RADIOISOTOPES;

EID: 84961950221     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011313.pub2     Document Type: Review

References (74)

1. Kolligs F, Bilbao J, Jakobs T, Iñarrairaegui M, Nagel J, Rodriguez M, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver International 2015; Vol. 35, issue 6:1715-21.
2. Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, et al. Safety and toxicity of radioembolization plus sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver International 2015;35:620-6.
3. El Fouly A, Ertle J, El Dorry A, Shaker M, Dechêne A, Abdella H, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. Liver International 2015;35:627-35.
4. Kulik L, Vouche M, Koppe S, Lewandowski R, Mulcahy M, Ganger D, et al. Prospective randomized pilot study of Y90 +/- sorafenib as bridge to transplantation in hepatocellular carcinoma. Journal of Hepatology 2014;61(2):309-17.
5. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826-37.
6. An Investigator Initiated Multicenter Prospective Randomised Study of Chemoembolisation Versus Radioembolisation for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial). Ongoing study August 2009..
7. Transarterial Radioembolisation Versus Chemoembolisation for the Treatment of HCC: a Multicenter Randomised Controlled Trial (TRACE trial).. Ongoing study September 2011..
8. A Prospective Randomised Open-Labelled Trial Comparing Radioembolisation with Yttrium 90 Microspheres and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.. Ongoing study December 2011..
9. A Phase III Clinical Trial of Intra-Arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma.. Ongoing study Primary outcome:overall survival..
10. A Randomized, Multi-center, Open Label, Phase 3 Trial Comparing Conventional TACE and Transarterial Radioembolisation in Patients with Unilobar Advanced Hepatocellular Carcinoma.. Ongoing study April 2013..
11. Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiouny M, Ellithy M. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. Journal of the Egyptian National Cancer Institute 2014; Vol. 26, issue 1:9-13. [DOI: 10.1016/j.jnci.2013.08.003]
12. Abdel-Rahman O, Elsayed Z. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Digestive Disease and Science 2013;58(12):3389-96. [DOI: 10.1007/s10620-0132872-x]
13. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines 3: rating the quality of evidence - introduction. Journal of Clinical Epidemiology 2011;64:401-6.
14. Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World Journal of Gastroenterology 2008;14(28):4445-53.
15. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
16. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-2.
18. Cochrane Hepato-Biliary Group Module. hbg.cochrane.org 2015 (accessed 23 March 2015).
19. D'Avola D, Lñarrairaegui M, Bilbao JI, Martinez-Cuesta A, Alegre F, Herrero JI, et al. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepato-gastroenterology 2009;56(96):1683-8.
20. DeMets DL. Methods of combining randomised clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
22. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012;56(4):908-43.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315:629-34.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45(2):228-47.
25. Functional Assessment of Cancer Therapy-Hepatobiliary tumors (FACT-Hep). www.facit.org/FACITOrg/Questionnaires (accessed 20 November 2015).
26. Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows. Grade Working Group 2004-2007, 2008.
27. Graham J, Newman D, Smirniotopolous J, Shetty K, Slidell M, Johnson L. Transplantation for hepatocellular carcinoma in younger patients has an equivocal survival advantage as compared with resection. Transplantation Proceedings 2013;45(1):265-71.
28. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knotterus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64:380-2.
29. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383-94.
30. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64:395-400.
31. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines 4: rating the quality of evidence - risk of bias. Journal of Clinical Epidemiology 2011;64:407-15.
32. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines 5: rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64:1277-82.
33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.) 1999;319:670-4.
35. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997.
36. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomised trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
37. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: down staging to resection, RFA and bridge to transplantation. Journal of Surgical Oncology 2006;94:572-86.
38. Kwon O, Jung Y, Bae K. Anti-hepatitis B core positivity as a risk factor for hepatocellular carcinoma in alcoholic cirrhosis: a case-control study. Alcohol (Fayetteville, N.Y.) 2012;46:537-41.
39. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002;50(6):881-5.
40. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial down staging for hepatocellular carcinoma: chemoembolization versus radioembolization. American Journal of Transplantation 2009;9(8):1920-8.
41. Liu C, Duan LG, Lu WS, Yan LN, Xiao GQ, Jiang L, et al. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou Criteria Staging Systems. PLoS One 2014;9(8):e103228.
42. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
43. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20:641-54.
44. Maffione AM, Ferretti A, Vinjamuri S, Rubello D. The PERCIST criteria: an insightful appraisal. Nuclear Medicine Communications 2013;34(7):619-20.
45. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;2(4):719-48.
46. Masuzaki R, Yoshida H, Omata M. Hepatitis C and hepatocellular carcinoma. Hepatocellular Carcinoma Diagnosis and Treatment. New York: Humana Press, 2009:45-50.
47. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine 1996;334:693-9.
48. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
49. Murthy R, Mutha P, Gupta S. Yttrium-90 radioembolotherapy for hepatocellular cancer. Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care. New York: Springer, 2011:50-60.
50. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918-28.
51. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2]
52. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
53. The Nordic Cochrane Centre, Cochrane. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, Cochrane, 2014.
54. Rhee TK, Omary RA, Gates V, Mounajjed T, Larson AC, Barakat O, et al. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. Journal of Vascular and Interventional Radiology 2005;16:1085-91.
55. Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. Journal of Hepatology 2011;54(4):695-704.
56. Royle P, Milne R. Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
57. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138(1):52-64.
58. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15(Suppl 4):14-22.
59. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
60. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
61. Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung ChW, et al. Hepatitis C virus and other risk factors in hepatocellular carcinoma. Acta Virologica 2012;56(3):235-40.
62. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
63. Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD006935.pub2]
64. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
65. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
66. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 10 February 2016).
67. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
68. Vente M, Wondergem M, Van Der Tweel I, Van den Bosch M, Zonnenberg B, Lam M, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. European Radiology 2009;19(4):951-9.
69. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD003046.pub3]
70. Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD006745.pub3]
71. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
72. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology 2009;9:86.
73. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
74. Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World Journal of Gastroenterology 2008;14(42):6437-41.